Therefore, these data employing in vitro, ex vivo, and in vivo models of hyperglycemia advocate the possibility of S-nitrosylation-mediated regulation of EZH2 as a potential therapeutic strategy to counter diabetic vascular complications. The gene discussed is EZH2; the disease is Hyperglycemia.